Developing a Nomogram for Dose Individualization of Phenytoin in Asian Pediatric Patients Derived From Population Pharmacokinetic Modeling of Saturable Pharmacokinetic Profiles of the Drug

2013 ◽  
Vol 35 (1) ◽  
pp. 54-62 ◽  
Author(s):  
Fiona X. L. Lee ◽  
Sing Teang Kong ◽  
Derrick W. S. Chan ◽  
Eli Chan ◽  
Wei Wei Tan ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Pharmacokinetic Modeling ◽  
Population Pharmacokinetic ◽  
Dose Individualization ◽  
Population Pharmacokinetic Modeling ◽  
Pharmacokinetic Profiles

scholarly journals Gentamicin Population Pharmacokinetics in Pediatric Patients—A Prospective Study with Data Analysis Using the saemix Package in R

Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1596
Author(s):  
Paolo Paioni ◽  
Vera F. Jäggi ◽  
Romy Tilen ◽  
Michelle Seiler ◽  
Philipp Baumann ◽  
...  
Keyword(s):  
Prospective Study ◽  
Plasma Levels ◽  
Pediatric Patients ◽  
Plasma Concentrations ◽  
Compartment Model ◽  
R Package ◽  
Pharmacokinetic Modeling ◽  
Therapeutic Window ◽  
Population Pharmacokinetic ◽  
Population Pharmacokinetic Modeling

The aminoglycoside gentamicin is used for the empirical treatment of pediatric infections. It has a narrow therapeutic window. In this prospective study at University Children’s Hospital Zurich, Switzerland, we aimed to characterize the pharmacokinetics of gentamicin in pediatric patients and predict plasma concentrations at typical recommended doses. We recruited 109 patients aged from 1 day to 14 years, receiving gentamicin (7.5 mg/kg at age ≥ 7 d or 5 mg/kg). Plasma levels were determined 30 min, 4 h and 24 h after the infusion was stopped and then transferred, together with patient data, to the secure BioMedIT node Leonhard Med. Population pharmacokinetic modeling was performed with the open-source R package saemix on the SwissPKcdw platform in Leonhard Med. Data followed a two-compartment model. Bodyweight, plasma creatinine and urea were identified as covariates for clearance, with bodyweight as a covariate for central and peripheral volumes of distribution. Simulations with 7.5 mg/kg revealed a 95% CI of 13.0–21.2 mg/L plasma concentration at 30 min after the stopping of a 30-min infusion. At 24 h, 95% of simulated plasma levels were < 1.8 mg/L. Our study revealed that the recommended dosing is appropriate. It showed that population pharmacokinetic modeling using R provides high flexibility in a secure environment.

Population Pharmacokinetic Modeling of Pantoprazole in Pediatric Patients From Birth to 16 Years

2011 ◽  
Vol 51 (3) ◽  
pp. 333-345 ◽  
Author(s):  
W. Knebel ◽  
B. Tammara ◽  
C. Udata ◽  
G. Comer ◽  
M. R. Gastonguay ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Pharmacokinetic Modeling ◽  
Population Pharmacokinetic ◽  
Population Pharmacokinetic Modeling

Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients

2015 ◽  
Vol 54 (8) ◽  
pp. 875-883 ◽  
Author(s):  
William Knebel ◽  
Mary Corcoran ◽  
James Ermer ◽  
Marc R. Gastonguay
Keyword(s):  
Pediatric Patients ◽  
Pharmacokinetic Modeling ◽  
Population Pharmacokinetic ◽  
Population Pharmacokinetic Modeling

Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor

2016 ◽  
Vol 33 (7) ◽  
pp. 1657-1670 ◽  
Author(s):  
Maiara Cássia Pigatto ◽  
Bibiana Verlindo de Araujo ◽  
Bruna Gaelzer Silva Torres ◽  
Stephan Schmidt ◽  
Paolo Magni ◽  
...  
Keyword(s):  
Solid Tumor ◽  
Pharmacokinetic Modeling ◽  
Population Pharmacokinetic ◽  
Population Pharmacokinetic Modeling
Sign in / Sign up

Export Citation Format

Share Document